Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally tolerated medical therapy demonstrated reduced rates of hospitalizations and death after being treated with the transcatheter MitraClip device. Patients in the randomized COAPT trial also showed improved quality-of-life and functional capacity.

September 26, 2018 — Bruker recently announced the introduction of the new preclinical PET/CT Si78 scanner for whole-body molecular imaging at the World Molecular Imaging Congress, Sept. 12-15 in Seattle.

Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference. This is the first head-to-head drug-eluting stent trial in the superficial femoral artery (SFA). Results were also presented at the annual Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress in Lisbon, Portugal. The clinical findings will be published in The Lancet.

September 25, 2018 – New data demonstrate the correlation between the presence of non-flow-limiting, non-intervened-upon, lipid-rich plaques and the development of a major adverse cardiac event (MACE) from a de novo culprit lesion.

Suboptimal cardiovascular ultrasound imaging can produce transthoracic echocardiograms (TTEs) that are inconclusive, resulting in negative patient outcomes and financial implications such as added costs for more testing. See why cSound software-beamforming technology from GE Healthcare addresses these challenges to potentially lessen patient burden, lower costs and improve patient care.

Download INFOGRAPHIC 

Orchestra BioMed Inc. announced the three-year clinical results from its Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2018, Sept. 21-25 in San Diego. Results demonstrated excellent efficacy and safety performance of the Virtue Sirolimus-Eluting Balloon (SEB) in a very challenging patient population with predominantly long, diffuse restenosis lesions within stents that had been implanted an average of nearly four years prior to the study enrollment.

Five-month-old Jack Palmer is home with his family in Kansas City after undergoing an extremely rare heart-lung transplant at St. Louis Children’s and Washington University Heart Center in May. At five months of age, Jack was the youngest patient to undergo this surgery successfully in more than a decade.

Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study evaluating the safety of the investigational AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR). The data was presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Sept. 21-25 in San Diego.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now